Yonhap Infomax NewsCelltrion's Zymfentra and biosimilar portfolio positioned for structural growth as US CMS Medicare policy changes favor lower-priced drugs through increased insurer contributions, higher patient cost caps, and preference shift toward self-administered subcutaneous formulations over intravenous treatments
#YonhapInfomax #Celltrion #Zymfentra #Biosimilars #CMS #MedicareAdvantage #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=114387
#YonhapInfomax #Celltrion #Zymfentra #Biosimilars #CMS #MedicareAdvantage #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=114387
Celltrion Eyes Windfall for Zymfentra, Biosimilars from US CMS Policy Overhaul
Celltrion's Zymfentra and biosimilar portfolio positioned for structural growth as US CMS Medicare policy changes favor lower-priced drugs through increased insurer contributions, higher patient cost caps, and preference shift toward self-administered subcutaneous formulations over intravenous treatments